Filing Flows › Longeveron (LGVN) › Q1 2026 › vs Q4 2025
Longeveron (LGVN) Q1 2026 vs Q4 2025 (quarter over quarter)
Longeveron's revenue rose $33K (+9%) from $365K in Q4 2025 to $398K in Q1 2026. The biggest changes: Clinical Trial Revenue +$75K (+25%); Contract Manufacturing Revenue −$37K (-65%).
Longeveron, Q1 2026: revenue $398K (+4% year over year), net loss $4.7M, operating cash flow −$4.4M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Clinical Trial Revenue | $378K | $303K | $75K | +25% |
| Contract Manufacturing Revenue | $20K | $57K | −$37K | -65% |
| Revenue | $398K | $365K | $33K | +9% |
| Other income, net | $39K | −$45K | $84K | — |
| Net loss | $4.7M | $5.4M | −$708K | -13% |
| Costs & expenses | $5.2M | $5.8M | −$636K | -11% |
| Operating costs | $5.2M | $5.8M | −$591K | -10% |
| Cost of revenue | $134K | $108K | $26K | +24% |
| Research & development | $2.3M | $2.7M | −$401K | -15% |
| General & admin | $2.7M | $2.9M | −$216K | -7% |
| Operating cash sources | $5.0M | $6.0M | −$949K | -16% |
| Depreciation & amortization | $252K | $278K | −$26K | -9% |
| Share-based compensation | $379K | $376K | $3K | +0.8% |
| Cash used in operations | $4.4M | $5.3M | −$926K | -17% |
| Net loss absorbed | $4.7M | $5.4M | −$708K | -13% |
| Working capital & other | $265K | $506K | −$241K | -48% |
Questions
How much did Longeveron's revenue grow quarter over quarter in Q1 2026?
Longeveron's revenue rose $33K (+9%) from $365K in Q4 2025 to $398K in Q1 2026.
What drove Longeveron's revenue change in Q1 2026?
Clinical Trial Revenue +$75K (+25%); Contract Manufacturing Revenue −$37K (-65%).